H19 Marker Identified in Resistant Leukemia Cells
Researchers have discovered that H19 gene expression increases in drug-resistant myeloid leukemia cells.
Updated on Sept. 21, 2026 in Cancer
Scientists have identified that the long non-coding RNA H19 is upregulated in myeloid leukemia cells that have developed resistance to azacitidine. This laboratory finding sheds light on the molecular changes that occur in cancer cells after prolonged exposure to the medication.
Why it matters
Understanding the molecular markers that emerge during treatment resistance is a critical step in identifying how leukemia cells survive therapy. This study helps researchers map the epigenetic reprogramming that occurs in cancer cells when they no longer respond to standard drugs.
In a laboratory analysis of K562 and HEL myeloid leukemia cell lines, researchers used RNA sequencing to identify elevated H19 levels following prolonged azacitidine exposure. The study found that neither increasing nor decreasing H19 expression altered the drug sensitivity of the cells.
The details
To create the resistant model, researchers exposed leukemia cells to azacitidine over a long duration until the cells demonstrated increased viability and a diminished apoptotic, or programmed cell death, response. While the resulting genetic profile showed higher H19 expression, suggesting it serves as a sign of epigenetic reprogramming, further testing proved this marker does not directly regulate the drug response itself.
Timeline
September 21, 2026: The research findings were published.
Health Landscape
This finding sits within the broader scope of research into the epigenetic mechanisms of drug resistance in acute myeloid leukemia. It adds to the catalog of molecular shifts that cells undergo to adapt to standard chemotherapy, distinguishing markers of resistance from actual drivers of the process.
This is a laboratory discovery focused on the behavior of cancer cells and does not change current treatment protocols or clinical recommendations. If you or a loved one are managing leukemia, focus on maintaining an open dialogue with your oncology team regarding the best available therapies.
The takeaway
While H19 expression is a reliable marker of cellular change in resistant leukemia, it is not a direct cause of drug failure. Patients and their families should continue to discuss individual treatment efficacy and clinical trial options directly with a hematologist-oncologist.
Further reading
For more background on the evolving understanding of malignancy, visit the Cancer section.
More information
View the full details in the peer-reviewed research article published this month.
Source note: This article includes information reported by Nature.
